Lombard Odier Asset Management Europe Ltd Has $11.35 Million Stock Holdings in IQVIA Holdings Inc. $IQV

Lombard Odier Asset Management Europe Ltd increased its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 34.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 50,330 shares of the medical research company’s stock after acquiring an additional 12,796 shares during the quarter. Lombard Odier Asset Management Europe Ltd’s holdings in IQVIA were worth $11,345,000 at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of IQV. AMG National Trust Bank acquired a new position in IQVIA during the 3rd quarter worth approximately $3,713,000. EDENTREE ASSET MANAGEMENT Ltd acquired a new stake in shares of IQVIA in the third quarter valued at approximately $7,368,000. Citigroup Inc. lifted its position in shares of IQVIA by 108.2% in the third quarter. Citigroup Inc. now owns 915,183 shares of the medical research company’s stock worth $173,830,000 after purchasing an additional 475,557 shares in the last quarter. Dana Investment Advisors Inc. grew its position in IQVIA by 18.4% in the third quarter. Dana Investment Advisors Inc. now owns 160,057 shares of the medical research company’s stock valued at $30,401,000 after purchasing an additional 24,854 shares in the last quarter. Finally, Strive Asset Management LLC acquired a new stake in IQVIA in the 3rd quarter valued at $17,447,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. Weiss Ratings cut IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Morgan Stanley set a $225.00 price target on IQVIA in a research report on Thursday, May 7th. Truist Financial reduced their price target on IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a research note on Thursday, February 19th. Mizuho set a $215.00 price objective on shares of IQVIA in a report on Monday, February 23rd. Finally, Royal Bank Of Canada initiated coverage on shares of IQVIA in a report on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 target price on the stock. Two analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, IQVIA presently has an average rating of “Buy” and an average target price of $224.13.

IQVIA Price Performance

Shares of NYSE:IQV opened at $179.04 on Wednesday. The firm has a 50 day moving average of $173.77 and a 200-day moving average of $192.69. IQVIA Holdings Inc. has a 12 month low of $153.01 and a 12 month high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20. The stock has a market capitalization of $29.88 billion, a PE ratio of 22.19, a PEG ratio of 1.53 and a beta of 1.21.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period last year, the firm posted $2.70 earnings per share. The firm’s quarterly revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts predict that IQVIA Holdings Inc. will post 11.6 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has initiated a stock repurchase plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s management believes its stock is undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.